|

Masupirdine 50 mg Clinical Trials

1 actively recruiting trial across 1 location

Also known as: SUVN-502

Pipeline

Phase 3: 1

Top Sponsors

  • Suven Life Sciences Limited1

Indications

  • Alzheimer's Type Dementia1
  • Agitation1
  • Alzheimer's Disease1

Anaheim, California1 trial

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Advanced Research Center, Inc.

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.